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ABSTRACT 
Vaccines have been shown to cause differential expression of genes and increase antibody titers against antigens.   
Influenza vaccines may have an effect on unexplained disorders such as Chronic Fatigue Syndrome/Myalgic Encepha-
lomyelitis (CFS/ME). Immunological changes have been identified following immunization with trivalent influenza 
vaccine (TIV). The objective of this pilot study was to examine the consequences of TIV on cytokine and cytotoxic 
genes in CFS/ME. Peripheral blood mononuclear cells were preferentially isolated from whole blood of 7 CFS/ME  
patients and 8 controls. Following total RNA extraction and synthesis of cDNA, reverse transcriptase-quantitative po-
lymerase chain reaction (RT-qPCR) was used to determine the expression levels of mRNAs for cytotoxic genes (per-
forin (PRF1), granzyme A (GZMA), granzyme B (GZMB) and cytokine genes. GZMB was significantly increased over-
all in the CFS/ME patients compared to the controls. GZMA was significantly increased 28 days after vaccination while 
PRF1 was reduced pre-vaccination but increased 14 days post-vaccination in the CFS/ME patients. There were no sig- 
nificant changes in cytokine genes pre or post vaccination. Administration of TIV may increase the expression of lytic 
genes in CFS/ME and this may contribute to the increase in cytotoxic activity we observed in these patients post vacci-
nation.  
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1. Introduction 
The effectiveness of seasonal vaccines such as the influ- 
enza vaccine is related to the ability to establish anti- 
genicity involving the type of vaccine generated and the 
strain of influenza vaccine present in the periphery [1]. 
Usually, the efficacy of a particular vaccine is condi- 
tional on intrinsic individual characteristic such as age, 
pre-existing antibody titers derived from vaccination or 
previous influenza infections and immune-competence of 
the individual [2]. Importantly, influenza vaccines are 
known to induce changes in the immune system in order 
to give a protective effect. In particular, trivalent inacti- 
vated influenza vaccine (TIV) can improve the titers of 
antibodies that are antigen specific. Similarly, both TIV 
and live attenuated influenza vaccine (LAIV) can stimu- 
late changes in genes that are associated with the inter-
feron (IFN) signaling pathway including IRF7, IRF3, 
STAT1 and STAT2 [3]. These molecular changes may be 
cell specific. For example, in mice TIV vaccines induce 
changes in genes related to dendritic cells and B cells [4].  
Administration of vaccines in patients with immune- 
compromised disorders is controversial, as there is a 
tendency for the vaccine to either exacerbate the symp- 
toms or further suppress the already compromised im- 
mune system, thus causing detriment to health [5]. Im- 
portantly, it is difficult to predict the benefits of vaccina- 
tion in people with diseases such as Chronic Fatigue 
Syndrome/Myalgic Encephalomyelitis (CFS/ME). CFS/ 
ME is largely a disease with unexplained mechanism(s) 
where a causal factor(s) currently remains unknown. 
Presently, the predominant method for identifying pa- 
tients with CFS/ME is based on self-report tests [6]. De- 
spite limitations in the diagnosis of CFS, impairments in  
immune function have been identified as important hall- *Corresponding author. 
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marks of CFS/ME. Essentially, Natural Killer (NK) cell 
cytotoxic activity has been identified as an important 
immune deficit that may have biomarker potential in 
CFS/ME [7]. 
We have previously illustrated that administration of 
TIV may alter some immune indices in CFS/ME patients 
including cytotoxic activity, FOXP3 and the secretion of 
certain cytokines [8]. The exact mechanism for explain- 
ing these observed changes has not been identified and it 
is likely that in CFS/ME vaccination with TIV may affect 
molecular processes. Incidentally, gene expression stud- 
ies have identified genes that may regulate immune, 
metabolic, endocrine and neurologic functions in CFS/ 
ME [9]. Hence, the aim of this pilot study was to explore 
the effects of vaccination with TIV on gene expression in 
patients with CFS/ME compared to non-fatigued controls. 
2. Method 
2.1. Subject Recruitment 
Ethical approval was obtained from the Bond University 
Human Research Ethics Committee (R0852A). The study 
included CFS/ME participants (n = 8; age = 48 years) 
and non-fatigued controls (n = 7; age = 38 years) [7]. The 
inclusion criteria for CFS/ME were based on the Centre 
for Disease Prevention and Control (CDC) 1994 case 
definition, while the non-fatigued controls were partici- 
pants with no medical history or symptoms of prolonged 
fatigue or illness of any kind [10]. Patients were recruited 
into a larger study investigating potential biomarkers for 
CFS/ME in 2009 [11] and volunteers were invited to 
participate in this pilot study before the influenza season 
in May 2011. All participants were screened by a general 
practitioner on site for contra-indications to vaccination 
as per the Australian immunization handbook [12]. Par- 
ticipants provided written consent and filled out a brief 
survey. A qualified medical doctor administered the TIV 
immunization, Influvac (Solvay Pharmaceuticals, Sydney, 
NSW). A volume of 0.5 mL in a pre-filled syringe con- 
taining 15 μg haemagglutinin of each of the three rec- 
ommended strains produced for the 2011 flu season 
((2011) A/California/, 7/2009 (H1N1)-like strain, A/ 
Perth/, 16/2009 (H3N2)-like strain and B/, Brisbane/60/ 
2008-like strain) was used. The vaccine was adminis- 
tered intramuscularly to the deltoid muscle.  
2.2. Sample Collection 
Venous blood samples (40 mL) drawn from all partici- 
pants were collected into EDTA tubes and analysed 
within three hours of collection. Peripheral blood mono- 
nuclear cells (PBMCs) were isolated from whole blood 
using Ficoll-hypaque (GE Healthcare, Uppsala, Sweden). 
Samples were collected prior to vaccination and 14 and 
28 days post vaccination. 
2.3. RNA Extraction and cDNA Synthesis 
Total RNA was extracted from PBMCs using the miR-
Neasy isolation kit (Qiagen, Hilden, Germany) according 
to manufacturer’s instructions. Concentration and purity 
of RNA was determined using the NanoDrop 3300 
(Thermo Scientific, Waltham, MA). Following RNA ex- 
traction and quantification, synthesis of RNA to cDNA 
was accomplished with the SuperScriptTM III First-Strand 
synthesis SuperMix for reverse transcriptase-quantitative 
polymerase chain reaction (RT-qPCR) (Invitrogen, Carls- 
bad, CA) according to the manufacturer’s instructions. 
Synthesized cDNA were diluted 1:20 and stored at −20˚C 
prior to RT-qPCR. 
2.4. RT-qPCR Analysis 
RT-qPCR was performed in a CFX96 Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA). The final 
reaction volume (10 µL) included 1 × iQ SYBR-Green 
Supermix (Bio-Rad, Hercules, CA), 200 nM of each 
primer and 4 µL of diluted cDNA. The RT-qPCR condi- 
tions were 95˚C for 3 minutes, followed by 45 cycles of 
95˚C for 10 s, 62˚C for 30 s and generation of melt 
curves at 65˚C to 95˚C for the detection of secondary 
amplicons [13]. All reactions were performed in tripli- 
cate with each reaction plate containing an equal number 
of CFS/ME and non-fatigued controls, a calibrator con- 
trol derived from a pool of all cDNA samples and a no 
template control. PCR amplification efficiencies (85% - 
100%) for each primer pair was calculated using a 4-log 
serial dilution of the calibrator sample and efficiency 
correction was applied to the data during analysis. 
2.5. Stability of Normalization Gene 
Determination of the most stable mRNA gene for nor- 
malization purposes was performed on the bio-rad CFX 
manager analysis software which allowed the compari- 
son of M-values for each of the housekeeping genes. 
GAPDH, PGK1, 18S and ACTIN-β were the housekeep- 
ing genes tested for stability. M-values greater than 1 
were rejected while an M-value less than 1 for a particu- 
lar gene was considered the most stable. 
2.6. Statistical Analysis 
The data generated from the PCR were evaluated using 
the CFX Manager v1.6 (Bio-Rad, Hercules, CA). Inter- 
assay variations were normalized using a calibrator sam- 
ple. Normalized expression (ΔΔCq) for the genes of in- 
terest was normalized to a calibrator control and refer- 
ence gene GAPDH. All values for expression were log2 
transformed. The results were analysed using GraphPad 
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Prism 5 (GraphPad Software, San Diego, CA). Results 
were statistically significant where P ≤ 0.05. Non-para- 
metric Mann-Whitney test was used in analysing all data. 
3. Results 
3.1. RT-qPCR for Reference Gene Selection 
As the stability of a reference gene is paramount for ac-
curate outcomes in gene expression studies, a number of 
reference genes were inspected to establish the best pos-
sible gene for this study. GAPDH was found to be the 
most stable of the other housekeeping genes PGK1, 18S 
and ACTIN-β. GAPDH was determined to be the most 
stable reference gene as its average expression was less 
than one (Figure 1). 
3.2. RT-qPCR for Lytic and Cytokine Genes 
The expression levels of 6 genes were examined in the 
CFS/ME patients and non-fatigued controls. These in-
cluded mRNA levels for lytic genes, PRF1, GZMA and 
GZMB, and cytokine genes IFN-G, TGF-B and TNF-A. 
In comparison to the non-fatigued controls, the CFS/ME 
patients, lytic proteins were significantly altered before 
and after vaccination. PRF1 was the only gene that was 
significantly decreased in the CFS/ME patients prior to 
vaccination (Figure 2). However, PRF1 was increased 
14 days after vaccination while GZMA was increased 28  
 
 
Figure 1. Determination of the appropriate reference gene 
for gene expression based on M-values (average expression). 
The stability of the reference genes (Actin, 18S, GAPDH 
and PGK1) was examined to determine the most stable ref- 
erence gene suitable for this study. Each bar in the graph 
above represents the average expression of all participants 
for a particular reference gene. The dashed line represents 

































Figure 2. Analysis of PRF1 expression pre- and post-vacci- 
nation. The expression profile of PRF1 at baseline prior to 
vaccination, 14 and 28 days post-vaccination and the overall 
expression of these genes following a pooled analysis of all 
time points is presented. The grey box plots are representa- 
tive of control data while the black box plots represent 
CFS/ME data. The boxes are indicative of the interquartile 
range (25% - 75%), with the median illustrated by the 
presence of the horizontal bars within the boxes and the 
whiskers below and above are symbolic of the minimum 
and maximum data sets. *P-values ≤ 0.05. 
 
days after vaccination in the CFS/ME group (Figures 2 
and 3). An overall increase in GZMB was noticed in the 
pooled CFS/ME patients sample in comparison to the 
non-fatigued controls (Figure 4). Cytokine genes were 
not significantly different between groups prior or post 
vaccination (data not shown). 
4. Discussion 
The results from this pilot investigation suggest that TIV 
may enhance the expression of lytic genes in patients 
with immune-compromised disorders such as CFS/ME. 
Prior to vaccination there was a trend towards reduced 
mean fold in PRF1 expression in the CFS/ME patients 
compared to the non-fatigued controls. Both granzyme 
genes were similar in expression in the two groups. 
However, PRF1 and GZMA were significantly increased 
14 days and 28 days after vaccination, respectively. 
There were no observable changes in cytokine expression 
prior or post vaccination. 
Previous reports have provided evidence in support of 
molecular changes following vaccination. In most of 
these studies, an upregulation in immune related genes 
has been observed in healthy individuals after vaccina- 
tion. The pattern of response and the effects on molecular 
processes are time dependent and most often extreme 
expression changes have been observed in the first 24 
hours following vaccination [13].  
PRF1, GZMA and GZMB are translated in to perforin 
and granzyme proteins which are predominantly found  
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Figure 3. Analysis of GZMA expression pre- and post-vacci- 
nation. The expression profile of GZMA at baseline prior to 
vaccination, 14 and 28 days post-vaccination and the overall 
expression of these genes following a pooled analysis of all 
time points is presented. The grey box plots are representa- 
tive of control data while the black box plots represent 
CFS/ME data. The boxes are indicative of the interquartile 
range (25% - 75%), with the median illustrated by the 
presence of the horizontal bars within the boxes and the 
whiskers below and above are symbolic of the minimum 
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Figure 4. Analysis of GZMB expression pre- and post-vacci- 
nation. The expression profile of GZMB at baseline prior to 
vaccination, 14 and 28 days post-vaccination and the overall 
expression of these genes following a pooled analysis of all 
time points is presented. The grey box plots are representa- 
tive of control data while the black box plots represent 
CFS/ME data. The boxes are indicative of the interquartile 
range (25% - 75%), with the median illustrated by the 
presence of the horizontal bars within the boxes and the 
whiskers below and above are symbolic of the minimum 
and maximum data sets. *P-values ≤ 0.05. 
 
in cytotoxic lymphocytes. These proteins are used to in- 
duce cellular apoptosis of viral infected cells [14,15]. 
During cytotoxic activity against viral infection, perforin 
forms pores in the cell membrane via a calcium depend- 
ent pathway enabling the release and delivery of gran- 
zymes into the target cell where they induce apoptosis 
[16-18].  
In the present study influenza vaccine enhanced the 
expression of PRF1 and this may be consistent with the 
finding that cytotoxic activity increased significantly 14 
days after vaccination in the CFS/ME patients compared 
to the non-fatigued controls [8]. IL-2R has been observed 
to heighten PRF1 expression particularly in CD8+T cells 
and reductions in IL-2R dampen the expression of PRF1 
[19,20]. A similar observation has been reported in NK 
cells in the presence of IL-2 [21,22]. In NK cells IL-2Rβ 
regulates the concentration of perforin [23] via Janus 
Kinase/STAT or the NFκB pathway. The JAK/STAT 
pathway results in the activation of STAT5 [19]. IL-2R 
signalling activates IKKα which results in the recruit- 
ment of IκBα and this stimulates the binding of NFκB 
components resulting in an enhanced PRF1 expression in 
NK cells [22]. Relatively low levels of IL-2 are present 
in the plasma during influenza infection causing a possi- 
ble reduction in NK related IFN-γ secretion and cyto- 
toxic activity [24]. Reduced cytotoxic activity is a hall- 
mark of CFS/ME and this may promote viral thrive, per- 
sistence and suppressed pathogen clearance. Influenza 
vaccines such as LIV have been reported to increase the 
production of IL-2 [25,26]. Thus, it is possible that ad- 
ministration of TIV provoked an excess in IL-2 or IL-2R 
consequently stimulating a significant increase in PRF1 
and cytotoxic activity. During influenza virus infection, 
cytotoxic cells in the respiratory tract lyse infected cells 
in the mucosal membrane, using the perforin pathway 
[27]. This is an important early response to influenza and 
ensures rapid clearance of the viral pathogens.  
The exact cause for the increase in GZMA after vacci- 
nation is currently unknown however, GZMA is known to 
promote pro-inflammatory cytokine release, hence the 
increase in GZMA may have induced significant in- 
creases in pro-inflammatory cytokines including TNF-α 
[28]. GZMA and GZMB have been shown to be de- 
creased in CFS/ME patients [7,29]. GZMB is an impor- 
tant marker of susceptibility to influenza in older adults 
[30]. Although, GZMB was markedly increased in the 
CFS/ME patients 14 days post-vaccination, it was not 
statistically significant. Similarly, cytokine mRNA ex- 
pressions were not significantly changed in the present 
study. Conversely in animal experiments, influenza in- 
creases IL-4, IL-5, IL-6 and IL-10 mRNA levels two 
days post vaccination [31], highlighting a potential in- 
fluence of time on changes in mRNA levels. Hence, 
measurement of expression changes at immediate time 
intervals maybe necessary for future studies as salient 
effects potentially occur immediately following vaccina- 
tion.  
At the molecular level vaccination against influenza 
may have a significant influence on the expression of 
immune related genes at different time points. These ef- 
fects occur only in the short run and do not persist over- 
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time. Therefore at the initial stages of vaccine introduc- 
tion in CFS/ME, these effects may be beneficial as they 
may cause a significant improvement in mechanisms 
such as cytotoxic activity that are observed to be de- 
creased in CFS/ME. Hence, vaccination may be protec- 
tive in the short run causing an improvement in immune 
function. Thus, it can be postulated that the increase in 
cytotoxic activity in the CFS/ME patients occurred as a 
consequence of influenza vaccination, leading to an in-
crease in PRF1 and a subsequent increase in cytotoxic 
activity. 
The limitations with this study pertain to the sample 
size, as a larger sample size may substantiate the results. 
As this was a pilot study, further investigations are now 
required using a large sample size and a broad spectrum 
of genes. This study has demonstrated salient changes in 
cytotoxic-related genes that may correlate with the func- 
tional status of NK cells in CFS/ME patients following 
vaccination. Moreover, whether these effects are detri- 
mental to CFS/ME immune health is yet to be proven as 
changes in lytic genes did not persist for the duration of 
the study. 
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